Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where C. Van Laer is active.

Publication


Featured researches published by C. Van Laer.


Acta Oto-laryngologica | 1997

Definition, Classification and Reporting of Meniere's Disease and its Symptoms

P. Van de Heyning; F.L. Wuyts; J. Claes; E. Koekelkoren; C. Van Laer; H. Valcke

This review describes the practicalities of using both the inner Ear Profile to define hydrops labyrinthi, and the American Academy of Otolaryngology and Head and Neck Surgery (AAO-HNS) guidelines to define Menieres disease. The requirement for standardisation is stressed since either system alone may be inadequate. It is suggested that the Inner Ear Profile could be adapted to the AAO-HNS criteria to create a unified method of evaluation.


Clinical Rheumatology | 2000

Endoscopic management of severe subglottic stenosis in Wegener's granulomatosis.

I. Stappaerts; C. Van Laer; K. Deschepper; P. Van de Heyning; P. Vermeire

Abstract: The optimal treatment for severe subglottic stenosis secondary to Wegener’s granulomatosis remains controversial. We report the case of a symptomatic middle-aged woman who was successfully treated with intratracheal dilation and intralesional injection of corticosteroids. The literature related to this issue is being reviewed.


Laryngoscope | 1990

Allograft tympanoplasty: Predictive value of preoperative status

J. Claes; P. Van de Heyning; W. L. Creten; E. Koekelkoren; C. Van Laer; D. De Saegher; A. Graff

The functional and anatomical results of a series of 181 consecutive allograft tympanoplasties for ears with drum perforation and an intact ossicular chain were retrospectively reviewed and related to preoperative factors. Drum closure was realized in 92% (166 of 181 cases evaluated 1 year after surgery), and 96.6% of the reconstructed drums were still intact 3 years after surgery (118 cases evaluated). An air‐bone gap of less than 21 dB was reached in 79.6% (of a total of 162 cases) 1 year after surgery, and in 78% (of a total of 118 cases) 3 years after surgery. Age, contralateral pathology, the wet or dry status of the ear preoperatively, and the preoperative air‐bone gap had no influence on anatomical results. The preoperative air‐bone gap did not predict the postoperative air‐bone gap. The influence of age and existence of contralateral pathology on hearing gain was only visible in some of the strictly defined patient groups. The wet preoperative status of the ear generally predicted lower functional gain.


Journal of Laryngology and Otology | 1996

Benign fibrous histiocytoma of the larynx: presentation of a case and review of the literature

C. Van Laer; Evert Hamans; I. Neetens; E. Van Marck; A. van Oosterom; P. Van de Heyning

A case of a benign histiocytoma of the larynx in a 39-year-old man is presented. Laryngeal fibrous histiocytoma is extremely rare. Its pathology is described including arguments for benignity. The literature is reviewed and management is discussed.


Dysphagia | 2018

Reply to the Letter to the Editor Concerning: ‘Changes in Swallowing-Related Quality of Life After Endoscopic Treatment for Zenker’s Diverticulum Using SWAL-QOL Questionnaire’

Charlotte Colpaert; Olivier M. Vanderveken; P. Van de Heyning; C. Van Laer

Siau et al. raise some interesting points regarding the results of the use of the SWAL-QOL questionnaire for the assessment of swallowing-related quality of life after endoscopic treatment for Zenker’s diverticulum (ZD) [1]. First, the notice of the fact that SWAL-QOL does not address the symptom of regurgitation should indeed be regarded as a limitation of its use for the evaluation of this particular symptom in ZD patients both at baseline as well as during follow-up after ZD treatment. Potentially, this shortcoming might lead to a validated modification of SWAL-QOL and/or other questionnaires towards a more ZD-oriented tool. In fact, this would envisage some modifications in terms of adding questions related to regurgitation. As this complaint, also in our study [1], is a common symptom in ZD patients (48% combining dysphagia and/or regurgitation as their main complaint) at presentation, this is indeed highly relevant. In addition, as clearly pointed out by Siau et al., relapse of this specific complaint might usually suggest ZD recurrence [2]. In our study, due to the short follow-up time, this was not an issue. Similarly, Skaug et al. added two questions specific to dysphagia (regurgitation and nightly mucus production) at the MD Anderson Dysphagia Inventory (MDADI) in order to make this dysphagia questionnaire more specific for patients with ZD [3]. Second, we believe that the high rates of participant’s non-engagement (37.5%) in our study is not mainly due to the relatively long time needed to fill out SWAL-QOL questionnaire, but rather due to the high age-related prevalence of ZD cohorts (mean age being 69 years in the present trial, and in other studies ranging from 68 up to 82 years [4, 5]), and the unwillingness and/or the potential difficulty to work with the computer. Another important aspect of our present trial is that the main goal of the authors was to assess and estimate mean SWAL-QOL baseline values in ZD patients seeking treatment. In addition, we were able to report on changes in SWAL-QOL values after endoscopic ZD treatment over a short postoperative follow-up period of 3 months on average. This follow-up in the present study is too short to draw conclusions on the role of SWAL-QOL in detecting ZD relapse, as previous studies have indicated that recurrence rate would occur over a median time of 7–43 months [5]. The role of the SWAL-QOL questionnaire in long-term follow-up of endoscopic treatment of ZD is currently the subject of ongoing and future clinical trials. In other words, the present study was neither aiming to evaluate the role of SWAL-QOL in the long-term follow-up nor planning to detect ZD recurrences because of the short-term assessment.


Annals of Oncology | 2007

Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck : long-term follow up data

Pol Specenier; D. Van den Weyngaert; C. Van Laer; Joost Weyler; J. Van den Brande; Marjan Huizing; J. Dyck; Dorien M. Schrijvers; J.B. Vermorken


B-ent | 2010

A neuroendocrine tumour of the sphenoid sinus and nasopharynx: a case report.

V. Vandist; F. Deridder; W. Waelput; P.M. Parizel; P. Van de Heyning; C. Van Laer


Dysphagia | 2017

Changes in Swallowing-related Quality of Life After Endoscopic Treatment For Zenker’s Diverticulum Using SWAL-QOL Questionnaire

C. Colpaert; Olivier M. Vanderveken; Kristien Wouters; P. Van de Heyning; C. Van Laer


European Journal of Cancer | 2015

2817 12-year Follow-up (FU) Data and late local toxicity Of Two Cohorts of patients with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) treated with Concomitant Chemoradiation (CCRT) With Or Without Induction Chemotherapy (ICT)

E. Dewaele; J.B. Vermorken; C. Verschueren; Olivier M. Vanderveken; C. Van Laer; S. Mariën; Pol Specenier


European Journal of Cancer | 2015

2822 Gemcitabine-based chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: A literature review and meta-analysis

Petr Szturz; Olivier M. Vanderveken; Pol Specenier; Marco Merlano; Marco Benasso; D. Van Gestel; Kristien Wouters; C. Van Laer; D. Van den Weyngaert; Marc Peeters; J.B. Vermorken

Collaboration


Dive into the C. Van Laer's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Van den Brande

Erasmus University Rotterdam

View shared research outputs
Top Co-Authors

Avatar

Marjan Huizing

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

J. Claes

University of Antwerp

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge